Related Experiment Video

Updated: Jul 12, 2026

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model
08:42

Skeletal Phenotype Analysis of a Conditional Stat3 Deletion Mouse Model

Published on: July 3, 2020

GSK-3beta controls osteogenesis through regulating Runx2 activity

Fumitaka Kugimiya1, Hiroshi Kawaguchi, Shinsuke Ohba

  • 1Center for Disease Biology and Integrative Medicine, University of Tokyo, Tokyo, Japan.

Plos One
|September 6, 2007
PubMed

Insights

Glycogen synthase kinase-3beta (GSK-3beta) deficiency enhances bone formation by boosting Runx2 activity. Inhibiting GSK-3beta may treat bone disorders like cleidocranial dysplasia.

Area of Science:

  • Bone biology and skeletal development
  • Molecular signaling pathways in osteogenesis
  • Genetic regulation of bone formation

Background:

  • Despite advances, the molecular mechanisms governing bone formation require further elucidation for clinical translation.
  • Understanding signaling pathways is crucial for developing treatments for bone disorders.
  • Runx2 is a key transcription factor in bone development, but its regulation is complex.

Purpose of the Study:

  • To investigate the role of glycogen synthase kinase-3beta (GSK-3beta) in regulating bone formation.
  • To determine if GSK-3beta influences the activity of the transcription factor Runx2.
  • To explore GSK-3beta as a potential therapeutic target for skeletal dysplasias.

Main Methods:

  • Utilized heterozygous GSK-3beta-deficient mice to study bone formation.
  • Assessed the transcriptional activity of Runx2 in the context of GSK-3beta deficiency.
  • Administered lithium chloride, a GSK-3beta inhibitor, to rescue cleidocranial dysplasia models.
  • Examined the effects of genetic GSK-3beta insufficiency on Runx2 phosphorylation.

Main Results:

  • Heterozygous GSK-3beta deficiency led to increased bone formation.
  • GSK-3beta deficiency enhanced Runx2 transcriptional activity by reducing inhibitory phosphorylation.
  • Genetic insufficiency of GSK-3beta or lithium chloride treatment rescued cleidocranial dysplasia phenotypes in Runx2-deficient mice.
  • GSK-3beta was identified as a key regulator of Runx2 activity.

Conclusions:

  • GSK-3beta acts as a critical negative regulator of Runx2 activity in bone formation.
  • Targeting GSK-3beta offers a potential therapeutic strategy for bone catabolic disorders.
  • This study highlights GSK-3beta as a promising molecular target for treating conditions like cleidocranial dysplasia.

More Related Videos

Preparation Of Gushukang (GSK) Granules for In Vivo and In Vitro Experiments06:16

Preparation Of Gushukang (GSK) Granules for In Vivo and In Vitro Experiments

Published on: May 9, 2019

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Activation and Inactivation of G Proteins01:22

Activation and Inactivation of G Proteins

Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high affinity and are together...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...